Evaluate the Efficacy of TIRZEPATIDE for the Treatment of Moderate to Severe HS Hidradenitis Suppurativa

NANot yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 11, 2024

Primary Completion Date

March 11, 2025

Study Completion Date

March 11, 2025

Conditions
Hidradenitis Suppurativa
Interventions
DRUG

TIRZEPATIDE

Tirzepatide injection contains tirzepatide, a once weekly dual receptor, GIP and GLP-1 receptor agonis t. It is a 39-amino-acid modified peptide with a C20 fatty diacid moiety that enables albumin binding and prolongs the half-life. The molecular weight is 4813.53 Da and the empirical formula is C225H348N48O68.

All Listed Sponsors
lead

Florida Academic Centers Research and Education, LLC

INDUSTRY

NCT06301256 - Evaluate the Efficacy of TIRZEPATIDE for the Treatment of Moderate to Severe HS Hidradenitis Suppurativa | Biotech Hunter | Biotech Hunter